Li Zhu-Ying, Tian Chun-Yan, Wang Xue-Hui, Liu Ya-Fang
Department of Respiratory Medicine, First Affiliated Hospital of Heilongjiang University of Chinese Medicine.
Department of Graduate, Heilongjiang University of Chinese Medicine.
Medicine (Baltimore). 2018 Nov;97(45):e12829. doi: 10.1097/MD.0000000000012829.
This study assessed the effectiveness and safety of Chinese herbal medicine Ping Chuan Ke Li (PCKL) for the treatment of patients with mild/ moderate persistent asthma.A total of 108 eligible patients with persistent asthma were included and were divided into a treatment group and a control group in this retrospective study. All 108 patients underwent oral montelukast. Additionally, subjects in the treatment group also received PCKL therapy. All patients in both groups were treated for a total of 1 month. The primary outcome of lung function was evaluated by the forced expiratory volume in one second (FEV1) and FEV1/forced vital capacity (FVC). The secondary outcome of quality of life was assessed by St. George's Respiratory Questionnaire (SGRQ). Moreover, adverse events (AEs) were also recorded in this study. All outcome measurements were assessed after 1-month treatment.After 1-month treatment, patients in the treatment group did not demonstrate better outcome in the improvement of lung function, measured by FEV1 (P =.57, table 2), and FEV1/FVC (P =.29); and enhancement of quality of life, measured by SGRQ scale (total, P =.37; symptom, P =.32; activity, P =.39; impact, P =.83). In addition, no AEs differ between 2 groups.The results of this study showed that Chinese herbal PCKL may not benefit for patients with mild/moderate persistent asthma after 1-month treatment.
本研究评估了中药平喘颗粒（PCKL）治疗轻/中度持续性哮喘患者的有效性和安全性。在这项回顾性研究中，共纳入了108例符合条件的持续性哮喘患者，并将其分为治疗组和对照组。所有108例患者均口服孟鲁司特。此外，治疗组患者还接受了PCKL治疗。两组所有患者均接受了为期1个月的治疗。通过一秒用力呼气容积（FEV1）和FEV1/用力肺活量（FVC）评估肺功能的主要结局。通过圣乔治呼吸问卷（SGRQ）评估生活质量的次要结局。此外，本研究还记录了不良事件（AE）。所有结局指标均在治疗1个月后进行评估。治疗1个月后，治疗组患者在以FEV1（P = 0.57，表2）和FEV1/FVC（P = 0.29）衡量的肺功能改善方面，以及以SGRQ量表衡量的生活质量提高方面（总分，P = 0.37；症状，P = 0.32；活动，P = 0.39；影响，P = 0.83）均未表现出更好的结局。此外，两组之间的不良事件无差异。本研究结果表明，中药PCKL在治疗1个月后可能对轻/中度持续性哮喘患者无益处。
